Connect your AI

Disc Medicine IRON Proceeds from issuance of common stock relating to employee stock plans

Proceeds from issuance of common stock relating to employee stock plans at other companies

Beam TherapeuticsBEAM

——

BridgeBio PharmaBBIO

——

Other financials

Income statement

Operating income-$69.5M-74.0%

Net income-$63.5M-86.3%

EPS (diluted)-$1.65-61.8%

Balance sheet

Cash & equivalents$88.9M-27.5%

Total debt$31.1M+1.4%

Total equity$688.4M+4.3%

Total assets$750.2M+5.8%

Cash flow

Operating cash flow-$62.2M-50.4%

CapEx--100%

Free cash flow-$62.2M-47.4%

Valuation

Market cap$2.69B+42.2%

Enterprise value$2.63B+46.7%

Returns & leverage

Return on equity-35.8%+41.3pp

Debt / equity0×0.0×

Current ratio24×-13.6×

Where this comes from

Reported directly by Disc Medicine in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockPlans.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's proceeds from issuance of common stock relating to employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Disc Medicine's proceeds from issuance of common stock relating to employee stock plans?: Disc Medicine (IRON) reported proceeds from issuance of common stock relating to employee stock plans of $687K in Q1 2026.
How has Disc Medicine's proceeds from issuance of common stock relating to employee stock plans changed year-over-year?: Disc Medicine's proceeds from issuance of common stock relating to employee stock plans increased by 139.4% year-over-year, from $287K to $687K.